Neural Progenitor Cells: Better Biological Models of Neurodegenerative DiseaseDecember 06, 2018, at 12:00 PM ET
Scientists are challenged by the lack of advanced biological models of the nervous system to produce meaningful results that lead to better, more precise treatments for neurodegenerative diseases. As part of our pledge to provide validated models to better recapitulate in vivo systems, ATCC has created neural progenitor cells (NPCs) from normal and Parkinson’s disease-derived induced pluripotent stem cells. NPCs are ideal in vitro models as they can be induced to differentiate down all three neural lineages. In this webinar we will focus on the Parkinson’s disease-derived NPCs, detailing their neural biomarker expression profiles during dopaminergic neuron differentiation and validating their use in toxicological studies.
- NPCs cultured in ATCC Dopaminergic Neuron Differentiation Media express tyrosine hydroxylase and TuJ1
- Normal and Parkinson’s disease patient-derived NPCs can be induced to differentiate into early neurons, dopaminergic neurons, astrocytes, and oligodendrocytes
- Normal and Parkinson’s disease patient-derived NPCs can be used for basic research of disease mechanisms and to screen compounds for toxicity
Brian Shapiro, PhD
Marketing Segment Manager, Oncology, ATCC
Brian A Shapiro, PhD, works to communicate the scientific breakthroughs of ATCC’s product development laboratories to the biomedical research community. Brian is the Executive Producer of ATCC's Podcast, Behind the Biology. Previously, he worked at Virginia Commonwealth University, where he investigated the role of pre-mRNA splicing in the multi-drug resistance of lung cancer. Dr. Shapiro attended the Medical College of Georgia, where his research focused on adrenal physiology as well as diseases of the epidermis.